As we await novel compounds from a relatively apathetic industry, we are resurrecting antibiotics of which we have an outdated understanding. and that carry the potential for substantial side effects: polymyxins.
Aileen Ahiskali, PharmD
Advertisement
Articles by Aileen Ahiskali, PharmD
Advertisement
Latest Updated Articles
- The Great Debate: Polymyxin B Versus Polymyxin E
Published: March 1st 2017 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Listeria Outbreak Update: 27 Illnesses and 6 Deaths Linked to Packaged Meals
2
Clesrovimab Lowers RSV Hospitalizations and Illness in Healthy Infants
3
FDA Approves IV Antbiotic, Contepo, for Complicated Urinary Tract Infections
4
FDA Clears Immuron’s IMM-529 For Clinical Testing in C difficile; Phase 2 Set to Begin in Australia
5
